Sitemap
Your Guide to Insight Reports: Understanding the Oncology Landscape
Will COVID-19 Trigger a Change in Oncology Research Practices?
WHO Declares Breast Cancer the Most Common Malignancy Worldwide
What’s Next? Helping Patients Navigate Through Clinical Trial Withdrawal
Virtual KOL Engagement: Building a Successful Outreach Strategy
Virtual Events and Telemedicine Are Here to Stay
Virtual Discussion Boards Offer Flexible Solutions for Outreach and Engagement
Virtual Collaboration Platforms Are a Valuable Marketing Tool for Life Science Companies
Virtual collaboration platforms – why they are a must
Venous Thromboembolism (VTE) and Risk of Depression in Patients With Cancer
Using Social Network Analysis to Identify Key Scientific Leaders
US Policy Change for Biologics and Biosimilars Could Save Medicare >$1 Billion
Understanding Patterns of Care in Europe to Identify Best Practices for Treatment of Adult Patients with AML
Turning Conference Contacts Into Engaged KOLs
Trends in Treating Patterns of US HemOncs
Treatment Patterns for Patients With De Novo Metastatic Cancer
Treating Brain Metastasis as a Distinct Disease
Trastuzumab Reduced Recurrence and Mortality in Patients With HER2-Positive Breast Cancer
Trastuzumab Deruxtecan Significantly Increased Survival in HER2-Low Metastatic Breast Cancer
Translating Computational Precision Oncology Into Clinical Practice
To Resist or Change: The Impact of the “Digital Revolution” on Medical Journal Publications
Timing and Prognosis of Brain Metastases in Patients With Breast Cancer
Three Trends in Satellite Symposia
The various types of opinion leaders: What’s in a name?
The Value That Aggregated Treatment Data Provides to Life Science Companies
The Value of KOLs in Oncology and Hematology
The Value of Collaboration: How Life Science Companies Can Use Insight Reports to Improve Cancer Care
The Unintended Impact of COVID-19 Lockdowns on Cancer Care
The Positive Impact Insight Reports Can Have on Clinical Research Plans
The Ongoing Quest for Optimal Immunotherapy Combinations
The Net Effect of CAR T-Cell Therapy Remains Favorable
The Link Between Excess Weight and Risk of Second Cancers
The Importance of Pre- and Post-Event Engagement Strategies Developed Around Pharma Conferences
The Importance of Patient Perspectives in Medical Research: Key Takeaways From ISMPP’s 19th Annual Meeting
The Importance of Conference Coverage
The High Cost of Anticancer Medicine Wastage
The Growing Importance of Access to Health Systems and Integrated Delivery Networks
The Global Use of Medicine in 2019 (and Outlook for 2023)
The Future of Oncology Conferences and Expert Meetings After COVID-19
The Future of Imaging in Prostate Cancer
The Forgotten KOLs: Community Oncologists
The Changing Landscape of Multiple Myeloma Treatment
The Broadening Clinical Relevance of BRCA1 and BRCA2 Genetic Testing
The Benefits of Digital Features for Medical Publications
Telephone Visits Bridge the Gap to Vulnerable Populations
Teleoncology Practices Are Transforming Patient Care
Superior Progression-Free Survival With Trastuzumab Deruxtecan vs Trastuzumab Emtansine
Suicide Risk Among Physicians Continues to Rise
Strengthening digital approaches to improve HCP engagement strategies
Statin Use Associated With Reduced Breast Cancer Mortality Among Women
Standardization of Cell-Free DNA Testing in Oncology
Risk for Myeloid Neoplasms After CAR T-Cell Therapy
Rising to Industry Challenges: Prove Yourself as a Vital Partner in Maintaining Stakeholder Relationships
Results From Many Lung Cancer Clinical Trials Go Unpublished
Responsible Use of Social Media for Oncologists
Racial Disparities in Breast Cancer Survival Extend Beyond Socioeconomics
Proven Engagement Strategies for Hematologists and Oncologists
Promising Trends in Lung Cancer Survival
Priority Review for Zanubrutinib in Mantle Cell Lymphoma
Prescription Drug Prices Rising Sharply in the US
Pregnancy After Breast Cancer Was Not Associated With Adverse Outcomes in BRCA Carriers
Predicting Toxicity to Anti–PD-1/PD-L1 Checkpoint Therapy
Post-conference Season: 5 Things to Do After the Conference Ends
Positive and Negative Trends Reported in the Wake of COVID-19
Polypharmacy and Drug Interactions in Patients With Breast Cancer Receiving CDK4/6 Inhibitors
Physicians Report a Preference for Virtual Meetings and Events
Physician Perspectives in Lung Cancer: An Interview With Jagathi Devi Challagalla, MD
Patterns of Care in Adolescents and Young Adults With Acute Lymphoblastic Leukemia
Overview of potential treatments for COVID-19
Outlook for Market Access Opportunities in the US in 2022 and Beyond
Oral Anticoagulants Provide an Alternative for Treating VTE in Patients With Cancer
Optimizing treatment decisions for patients with FL and DLBCL: current opinion on decision-making criteria and first and second line treatment options
Open Dialogue Facilitates Optimized Dosing and Management of Treatment-Related Side Effects
Olaparib Improves PFS in HRR-Mutated Prostate Cancer
Obesity Associated With Increased Adverse Events in Nivolumab-Treated Patients
NIH to Fund US Research of Telehealth for Cancer Care
Newly approved at-home option for patients with HER2+ breast cancer
New Treatment Options In Oncology: FDA And EMA Drug Approvals In Q4 2022
New Treatment Options in Oncology: FDA and EMA Drug Approvals in Q4 2021
New Treatment Options in Oncology: FDA and EMA Drug Approvals in Q3 2023 – Broad Scope of Unique Targets and Malignancies
New Treatment Options in Oncology: FDA and EMA Drug Approvals in Q3 2022
New Treatment Options in Oncology: FDA and EMA Drug Approvals in Q2 2023 – Focus on DLBCL, NSCLC, and Biologics
New Treatment Options in Oncology: FDA and EMA Drug Approvals in Q2 2022
New Treatment Options in Oncology: FDA and EMA Drug Approvals in Q1 2023 – Focus on Solid Tumors
New Treatment Options in Oncology: FDA and EMA Drug Approvals in Q1 2022
New Support Tool for Immune-Related Adverse Events
New Gene-Phenotype Associations Discovered in a Large Analysis
New FDA Draft Guidance for Bispecific Antibodies
New FDA and EMA Oncology Drug Approvals in Q3 2024 Largely Focused on NSCLC and Other Solid Tumors
New FDA and EMA Oncology Drug Approvals in Q2 2024 Largely Focused on Biologics and Specific Molecular Targets
New Developments in Pharma Market Access in the US
New Developments in Pharma Market Access in the United States
New CAR T Therapy Approaches Gathering Pace
New Approval for Ramucirumab in Hepatocellular Carcinoma
New and Improved Approach to FDA Approval
Nearly Half of New FDA and EMA Oncology Drug Approvals in Q1 2024 Were Biologics or Biosimilars
NCCN Recognizes Bioimpedance Spectroscopy (BIS) for Lymphemedema Screening After Breast Cancer Treatment
Multicancer Tests Are On Track to Revolutionize Early Cancer Detection
MRD Helps Predict Outcomes in AML
Most New Cancer Drug Approvals Have Not Displaced Standards of Care
Mortality Risk Factors in Allogeneic Transplant Recipients
Metastatic Tumor Naming Needs to Change
Medical Publications Can Drive Engagement Through Digital Tools
Maximizing HCP Engagement and Access
Matched-Control Cohort Study of Tafasitamab in DLBCL Meets Primary Endpoint
Market Analysis Data Streamline the Pharma Brand Planning Process
Mandatory Counseling With Remote Cancer Genetic Testing May Cause More Harm Than Good
Managing social media during your event
Managing ALL and AML During COVID-19
Making the Most of Virtual Conferences: 5 Tips for Successful Virtual Meetings
Maintaining Quality of Care for Cancer Patients in the COVID-19 Pandemic
Linden to Invest in Aptitude Health
KOL Engagement in 2022 – A Reality Check
Key findings from global and regional insights-gathering events that will drive strategic decisions
Key findings from Aptitude Health global and regional insights-gathering events positively impact treatment decisions
International Multifaceted Virtual Programs Facilitate Insights-Gathering From Oncologists Worldwide
Inspiring Change in HCP Behavior Through Educational Interaction
Insights reports keep you informed and can trigger relevant strategic decision-making
Insights Into the “Why” Behind Patients’ Treatment Decisions
Insights into the “why” behind doctors’ treatment decisions
Insights Into Early Breast Cancer Favor Neoadjuvant Immune Checkpoint Inhibitor Therapy
Increasing Diversity in Clinical Trials to Address Disparities in Cancer Care
Increased Risk of Pneumonitis With Targeted Therapies in Breast Cancer
Increased Risk of GI Infection Among Elderly Cancer Patients
Including Male Patients With Breast Cancer in Clinical Trials
Improving awareness and advocacy in the field of oncology by strengthening stakeholder communication strategies
Impact of Patient Assistance Programs on Financial Toxicity in Oral Oncology Patients Managed Through Health System Specialty Pharmacies
Immunoglobulin vs Prophylactic Antibiotic in Patients With Hematologic Malignancies
Immune Checkpoint Inhibitors Improving OS in Small Cell Lung Cancer
Immune Checkpoint Inhibitor Rechallenge Caused Fewer, Less Severe AEs vs Initial Treatment
Immune Biomarkers Predict Survival Benefit With Immunotherapy in NSCLC
Identifying True Progression in Patients with Prostate Cancer
Identifying Older Adults With Cancer Who May Benefit From Geriatric Assessment
Identifying KOLs in the Field of Oncology: Why It’s Essential for Pharma Companies to Connect With the Entire Care Team
ICMJE Authorship and medical publications – part 2
HPV Vaccination Associated With Lower Risk of Invasive Cervical Cancer
How to Market Cancers That Fall Under the Rare Disease Umbrella
How to generate clinical research awareness
How to Enhance Your Presence at Oncology Conferences
How to Choose the Right Healthcare Consulting Company
How the COVID-19 Pandemic Changed KOL Engagement for Pharma Companies
How Pharma Communications Can Benefit From Virtual Meetings
How Pharma Can Digitize Interactions With HCPs
How Continuous Professional Development Reduces Healthcare Costs
High Rates of Chronic Pain in Cancer Survivors
High Prevalence of Sexual Dysfunction in Women With Lung Cancer
Healthcare providers’ perspectives on the cost of oral oncolytic agents and its impact during COVID-19
Health Information Technology Can Help Bridge Gaps in Cancer Genomic Testing
HCPs expect more online meetings in a post-COVID era: What does this mean for pharmaceutical marketers?
Harnessing the Potential of #MedEd for Medical Education on Social Media
Guidelines for Chemotherapy-Induced Peripheral Neuropathy Reflect a Continued Paucity of Evidence
Greatest Cancer Treatment Advances in 2020
Greater Clarity in NCCN Guideline Recommendations Could Improve Treatment Decisions
Global Efforts Are Needed to Curb the Substantial Cost of Cancer
Global Efforts Are Needed to Contain the Cost of Cancers
Giving Dasatinib With CAR T Cells May Reduce Risk of Side Effects
Geriatric Assessment Improves Outcomes for Older Patients With Advanced Cancer
Genetic Testing After Cancer Diagnosis Is Underutilized
Frequency of Treatment-Related Adverse Events for PD-1 and PD-L1 Inhibitors
First PI3K Inhibitor Approved in Breast Cancer
First CAR T-Cell Therapy Approved for Mantle Cell Lymphoma
Final FDA Guidance on AML Drug Development Released
FDA Releases Clinical Outcome Assessment Compendium
FDA Labeling Update for Capecitabine Under Project Renewal
Expert Perspectives: Prof Alexander Eggermont on Unmet Needs and Developments in the Field of Melanoma
Expert Perspectives on Rare Hematologic Diseases: A Focus on Castleman Disease With Dr Karthik Ramasamy
Expert Perspectives in Ovarian Cancer: A Conversation With Prof Christina Fotopoulou
Expert Perspectives in Multiple Myeloma: A Conversation With Dr Rafael Fonseca
Expert Perspectives in Melanoma: A Conversation With Dr Alexander Eggermont
Expert Perspectives in Management of Renal Cell Carcinoma: A Conversation With Sushil Bhardwaj, MD, FACP
Expert Perspectives in Management of NSCLC: A Conversation With William N. William, MD
Expert Perspectives in Management of NSCLC: A Conversation With Enriqueta Felip, MD, PhD
Expert Perspectives in Management of CRC: A Conversation With Tanios Bekaii-Saab, MD
Expert Perspectives in Gynecologic Oncology: A Conversation With Kathleen Moore, MD
Expert Perspectives in Gastric or GEJ Cancers: A Conversation With Julien Taieb, MD, PhD
Expert Perspectives in Cancer Care with Grigoris Gerotziafas, MD, PhD
Expert Perspectives in Breast Cancer: A Conversation With Marc Thill, MD, PhD
Expert Perspectives in Breast Cancer: A Conversation With Dr Joseph Gligorov
Expert Perspectives in Breast Cancer: A Conversation With Dr Joseph Gligorov
Expert Perspectives in Breast Cancer Surgery: A Conversation With Dr Pat Whitworth
Expert Perspectives in ALL: A Conversation With Nicola Gökbuget, MD
Excelera® and Aptitude Health Offer New Specialty Pharmacy Focused Educational Resources for Cancer Care
Evaluation of ChatGPT Accuracy for Cancer Information
ERBB2-Low Is Not a Distinct Early-Stage Breast Cancer Subtype
Enzalutamide Receives Priority Review for Hormone-Sensitive Prostate Cancer
Engaging KOLs Online: How to Stay Connected With Medical Experts
Engaging Conference Attendees Through Live Meetings
Emerging Oncology Trends: 2021 and Beyond
Emerging Oncology Trends
Emerging Disruptions: Pharma Marketing Trends You Can’t Ignore
Effective Virtual Meetings: A Global Online Hematology Event Case Study
Duration of Immunotherapy and Overall Survival in Advanced Non-Small Cell Lung Cancer
Drug Delivery Enhancement With Ultrasound and Microbubbles in the Treatment of Glioblastoma
Drug Approvals Increased in 2020, Despite the Pandemic
Dr Omid Hamid Describes New Immunotherapy Technology in Clear and Innovative Terms
Distributing Information on New Clinical Trials: How to Effectively Share Key Data
Demonstrating quality to stakeholders is critical in oncology marketing
Decreasing Cost of Care for Breast Cancer
Decision Support Tools for Surgical Referrals Improve Outcomes
Decision Model Aids Cancer Treatment Choices During the COVID-19 Era
Debate Over Widespread Next-Generation Sequencing Continues
Current Management of Renal Cell Carcinoma Features Immune Checkpoint Inhibitors
COVID-19 Has a Far-Reaching Impact on Cancer Patients
COVID-19 Fears Affect Clinical Trial Enrollment
Coronavirus Information for Clinicians
CORE Programs Provide Insights Into Axess Network Members’ Approach to Managing AML
Considerations for Overall Survival Analyses in Clinical Trials
Considerations for Hiring a Vendor for Medical Online Advisory Boards
Considerations for Clinical Trial Design to More Effectively Quantify Benefit in the Phase III Setting
Connecting with relevant HCPs
Confirmation of Clinical Benefits and Regulatory Outcomes Following Accelerated Approval
Conference Reports Deliver the Details and the Context
Conducting Smarter PubMed Searches – Part 2
Conducting Smarter PubMed Searches
Combination Targeted Therapy May Be Curative for Some Patients With DLBCL
Combating Medical Misinformation in Social Media
Clinical Prediction Model Calculates 1-Year Risk of Death in Advanced Cancer
Clinical Immersion Programs Keep Your Field Force Informed
Clinical Immersion Programs (HOLI) – Part 2
Circulating Tumor DNA Is a Promising Predictive Biomarker in Advanced Cancers
Characteristics of Long-term Survivors Guide Pancreatic Cancer Research
Changing the Code of Life: Nobel Prize in Chemistry 2020 Awarded for Discovery of CRISPR/Cas9 Genetic Scissors
Changing Practices in Hodgkin Lymphoma
Challenges and Risks of Asking AI Chatbots for Cancer Treatment Information
CDK4/6 Inhibitors Best Option for Metastatic HR+, HER2– Breast Cancer
CASES Summits: Understanding regional insights that drive strategic decisions
Cancer Survivors Report Disparities in Physician Cultural Competency
Cancer Patients and COVID-19: Lessons From China
Cancer Patients and COVID-19 Part 2: Lessons From Pooled Meta-Analyses
Cancer Cannot Be Shut Down: Use of Telemedicine During the COVID-19 Pandemic
Broad Scope of Unique Targets and Malignancies for New FDA and EMA Drug Approvals as 2023 Concluded
Bridging Tradition and Globalism: How to Add Value to Virtual Meetings
Boutique Agencies: Helping You Find a Path to Category Leadership in Oncology
Blood Type Linked With COVID-19 Risk
Bilateral Oophorectomy and All-Cause Mortality in Women
Beyond the Conference: How to Reenergize Your Message Post-congress
Best Strategies for PD-1 Inhibitor Combination Therapy
Authorship and medical publications
Assessing the Value of Diagnostic Tests
ASCO Vaccination Guideline Issued for Optimizing Vaccination Status Among Patients With Cancer
ASCO Announces 2021 Advance of the Year
Artificial Intelligence and the Future of Clinical Trials
Artificial Intelligence (AI) Computer-Aided Detection (CAD) Shows Promise for Breast Cancer Screening
Aromatase Inhibitors Are Less Effective in Women With Breast Cancer and Obesity
Are Medical Errors Overreported?
Aptitude Health’s Virtual Teambuilding Event
Aptitude Health’s 2022 Hematology and Oncology Conference Calendar
Aptitude Health Launches Real-World Evidence Registry Program and Research Network to Enhance Oncology Treatment Outcomes in the Community Setting
Aptitude Health Expands European Presence With Acquisition of UK-Based Bamboo Medical Communications Ltd
Aptitude Health Appoints Jez Moulding as CEO
Aptitude Health Acquires TME BCN
Aptitude Health Acquires Athena Meetings & Events, Organizer of the Annual UK Oncology Forum, to Strengthen Global Reach
Applying Remote Practices to Clinical Research
Antithrombotics Are Not Warranted in COVID-19 Outpatients
Answering the Question of Immunotherapy or Chemoimmunotherapy in Older Adults
American Cancer Society Reports a 33% Reduction in Cancer Deaths
Allowing HCPs to Drive the Pharma Marketing Conversation
Alleviating Cancer’s Financial Toxicity in the US Requires National Policy Changes
Aggressive End-of-Life Care Persists for US Nursing Home Residents With Metastatic Cancer
Adverse Effects of Telling Patients “We Got It All” After Cancer Removal Surgery
Addressing Social Determinants of Health
Achieving Equitable Access to Clinical Trials
Accelerated Physical Function Decline in Women With Cancer
Accelerated Approval for Pembrolizumab in Small Cell Lung Cancer
5 Steps to Nurture Up-and-Coming Leaders in Health Care
4 Tips for Managing Content That Will Improve Pharma Marketing Strategies
4 Oncology Insights You Can Gain From Conference Coverage Reports
3 Big Global Oncology Trends
2023 Tips for Strengthening KOL Engagement
2022 US Oncology Market Outlook: Trends and Challenges
